To further assess the potential of our combination therapy to induce a long-lasting tumor-specific CD8+ T cells response and promote memory development, we used B16-F10 and B16-mOVA (B16 cells expressing membrane-bound ovalbumin) melanoma cells in a model of tumor rechallenge that mimics tumor relapse in patients. This evidence concerns the gene CD8A and melanoma.